← All trials
NCT04813653
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 18, 2021
- Primary completion
- Apr 1, 2024
- Completion date
- May 1, 2024
- First posted
- Mar 24, 2021
- Last posted
- Apr 20, 2021
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tel Aviv UniversityLead sponsor
- Tel Aviv UniversityOverall official - principal investigator
- Weizmann Institute of ScienceCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.